Description: Luxdegalutamide (ARV-766) is an orally available and effective protein degrader of protein hydrolysis-targeted chimeras (PROTAC).Luxdegalutamide degrades the wild-type androgen receptor AR, as well as AR LBD mutants including those associated with the most prevalent pathogenic AR L702H, H875Y and T878A...

A PROTAC that drives androgen receptor degradation (DC50 = <1 nM), inhibits tumor growth in various LNCaP and VCaP prostate cancer mouse xenograft models, including an enzalutamide-insensitive, non-castrated VCaP model. Formulation: A solid. InChI:...